[{"orgOrder":0,"company":"TRIO Pharmaceuticals","sponsor":"FBVF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"CD33 TRAILBody","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"TRIO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRIO Pharmaceuticals \/ FBVF","highestDevelopmentStatusID":"4","companyTruncated":"TRIO Pharmaceuticals \/ FBVF"}]

Find Clinical Drug Pipeline Developments & Deals by TRIO Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CRS
                          Not Confirmed
                          CRS
                          Not Confirmed

                          Details : TRIO will use the net proceeds to advance cancer therapeutics pipeline, including CD33 TRAILBody in preclinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

                          Product Name : CD33 TRAILBody

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : CD33 TRAILBody

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : FBVF

                          Deal Size : $3.1 million

                          Deal Type : Series A Financing

                          blank